Autophagy induction pathway

The **autophagy induction pathway** refers not to a single molecule but rather a highly conserved cellular signaling cascade that initiates macroautophagic degradation—a process where cytoplasmic material is sequestered into double-membrane vesicles called autophagosomes for delivery to lysosomes. Induction is tightly regulated by nutrient status and stress signals through central kinases such as **mTOR** and **AMPK**, which converge on the **ULK kinase complex**. This leads sequentially to activation/nucleation events involving complexes like **Beclin‑1/class III PI3K/Vps34**, recruitment/expansion machinery (**ATG proteins**), cargo selection/adaptor proteins (**p62/SQSTM1**, NBR), membrane elongation/fusion factors (**LC3 lipidation system**), ultimately resulting in cargo degradation within lysosomes. This entire network is essential for maintaining cellular homeostasis under stress conditions but also plays context-dependent roles in diseases including cancer progression/suppression,[6], neurodegeneration,[6], cardiovascular injury,[4], metabolic disorders,[6], infection response,[6]. Pharmacological agents target specific nodes within this network rather than the overall “pathway.” The term “Autophagy induction pathway” does not refer specifically enough to any one druggable target; it encompasses multiple molecular targets with distinct functions throughout different stages.[5] Because it describes a multi-component biological process—not an individual protein/receptor/enzyme—the entry should be flagged as incorrect if used where only discrete molecular targets are appropriate.

Other names

Autophagy signaling pathwayAutophagy initiation pathwayMacroautophagy induction cascade

Drugs modulate this pathway primarily by affecting key regulatory kinases or complexes such as mTOR, AMPK, ULK1/ULK complex, Beclin‑1 complex, and class III PI3K/Vps34. Mechanisms include: – Inhibition of mTOR to activate ULK1/ULK complex and initiate autophagosome formation (e.g., rapamycin) – Activation of AMPK to promote catabolic processes including autophagy initiation (e.g., metformin) – Direct modulation of Beclin‑1 or Vps34 complexes involved in nucleation steps – Inhibition of lysosomal function to block completion of the process (e.g., bafilomycin A1)